| ID | 10230 |
| Vaccine Name | mRNA-1388 |
| Disease Name | Chikungunya fever |
| Disease Classification | Exanthous |
| Virus Name | Chikungunya virus |
| Nucleic Acid Content | positive-sense, single-stranded RNA |
| Vaccine Type | RNA based vaccine |
| Vaccine Status | Phase 1 |
| Manufacturer | Moderna Inc. |
| Year of Manufacturing | 2017 |
| Manufacturing Country | USA |
| Age | 18 - 49 years |
| Dosage | 3 doses on week 0, week 4, post 1 year |
| Administration Route | Intramuscular |
| Adjuvant | NA |
| Target Strain | CHIKV structural proteins |
| Description | mRNA based vaccine |
| Approving Organisation | NA |
| Collaborating Organisation | Defense Advanced Research Projects Agency |
| Other Countries | NA |
| Trade Name | NA |
| PMID | NA |
| Clinical Trial ID | NA |
| Reference Link | https://link.springer.com/chapter/10.1007/82_2019_175 |
| Additional Links | https://www.modernatx.com/pipeline/mrna-1388
|